New Drug Slows Dementia Psychosis by 89% as Phase 3 Trial Gets Green Light
Zervimesine dramatically slowed hallucinations and delusions in Lewy body dementia patients. A pivotal Phase 3 trial is set for mid-2027.
4,593 articles in this topic
Zervimesine dramatically slowed hallucinations and delusions in Lewy body dementia patients. A pivotal Phase 3 trial is set for mid-2027.
DiamiR and AlzLabs are combining protein and microRNA blood markers with AI tools to improve early Alzheimer's detection without brain scans.
CRISPR gene therapies targeting inherited Lp(a) and triglyceride risks move closer to human trials with $25M in new funding.
Human umbilical cord stem cell exosomes carrying Let-7 microRNAs restored hair growth in mice and increased hair density in a clinical trial.
A pharmacological cocktail transiently activates reprogramming genes in senescent endothelial cells, restoring function and improving blood flow in aged mice.
Epigenetic clock creator Dr. Steve Horvath joins Rhonda Patrick to explore how biological age is measured and reversed.
Harvard and Northeastern scientists used network medicine to screen 6,442 drugs against aging biology, revealing repurposing candidates for specific aging hallmarks.
A meta-analysis of 15,000+ methylation profiles finds conserved and tissue-specific aging patterns, spotlighting NAD+ and a cell-adhesion gene as key targets.
Dr. Don Brown joins Dr. Perlmutter to explain how AI integrates genomics and microbiome data to detect disease before symptoms appear.
Dr. Anurag Singh explains how activating mitophagy with urolithin A may upgrade cellular health, immunity, and muscle performance.
From temperature control to sound and stress tools, Greenfield breaks down the multi-layer nighttime routine behind elite sleep scores.
Ben Greenfield argues that temperature, light, EMF, and stress regulation fix sleep better than any supplement stack.